This Request for Information (RFI) seeks to identify organizations with AI capabilities for discovering broad-spectrum small-molecule therapeutics targeting filoviruses like Ebola and Marburg. The effort is expected to span AI-enabled discovery through preclinical in vivo testing in small animal models, with a preference for direct-acting antivirals showing activity across EBOV, SUDV, and MARV. Responses must be submitted by email to rrpv@ati.org no later than 1pm EDT on June 17th, 2026. No budget amounts are specified in this RFI, and the location for performance of services is not mentioned. This is a market research effort to inform future acquisition planning and does not constitute a solicitation for proposals.